Compare Matson Inc (MATX) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Nuwellis Inc — how do they compare? Matson Inc trades at $229 (market cap $6.67B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Matson Inc is far larger — about 3031.8× Nuwellis Inc's market cap, and Matson Inc pays a 0.68% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and Nuwellis Inc for 26 Days on average.
| MATX | NUWE | |
|---|---|---|
Market Cap | $6.67B | $2.20M |
Volume | 233,711 | 121,544 |
Sector | Industrials | Health |
52-Week High | $238.60 | $146.65 |
52-Week Low | $88.05 | $0.68 |
Typical Hold Time | 23 Days | 26 Days |
Enterprise Value | $7.26B | -$1.52M |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $222.92, down 0.83% today, with neutral technical signals and strong fundamental performance. The stock shows robust earnings momentum with three consecutive quarterly beats, including Q2 2026 EPS of $4.27 versus $3.79 expected. Revenue growth continues with 2026 projections reaching $3.5 billion, supported by a 13.4% net income margin. Recent news highlights institutional buying interest and positive analyst sentiment.
MATX presents a compelling investment case with solid profitability metrics and analyst support, though near-term technical resistance at $224 may limit upside. The company's raised full-year outlook and consistent dividend payments provide stability, while exposure to freight market volatility remains a key risk factor for shareholders.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
